Tagged with

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

Turkey Getinge’s president for Central and Eastern Europe, Ahmet Eke, comments on the strategic importance of the region for the Swedish company, the evolution of healthcare infrastructure in Turkey, and how Getinge competes in emerging markets against European and American medtech players.   Like many emerging markets, monetary resources are limited…

Turkey Prof. Hasan Mandal, president of the Scientific and Technological Research Council of Turkey (TÜBİTAK), explains how the COVID-19 platform coordinated by the agency has transformed the Turkish ecosystem by bringing together 436 researchers from 49 different institutions to collaborate on 17 drug and vaccine development projects. In addition, Prof. Mandal…

Turkey While supporters of Turkey’s localization policy for pharmaceuticals implemented in 2016 applaud the changes it has brought, its opponents are awaiting a much-anticipated report by the World Trade Organization that could put an end to the policy and have global repercussions.   Five years after the launch of Turkey’s localization…

MENA The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma multinationals explain what MEA means to their global groups and their key areas of focus today.   Biogen: Awareness is…

Global After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing sites in Latin America and Norway.   Bayer had a challenging year in 2020. While the German giant argued in…

Asia-Pacific Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led by Big Pharma, according to IQVIA. However, the region’s biotechs face a myriad of…

Denmark Newly appointed Director of Invest in Denmark Anne Hougaard Jensen outlines her initial priority list, how the agency is dialling in on the areas in which Denmark has a particular competitive advantage (life sciences, food, green technologies, and digital technologies), and her aspirations for keeping Denmark ahead of the curve…

Turkey General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just one month after the World Health Organization made an official pandemic declaration. In addition, she categorizes the government’s response to…

Saudi Arabia Khaled Harb, general manager of Saudi distributor Abdulrehman Algosaibi, highlights the changing distribution landscape in Saudi Arabia, the importance of offering comprehensive solutions that go beyond traditional services, what the updated role of procurement body NUPCO means for the industry, and shares his perspective on the Vision 2030 transformation.  …

Denmark Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the swift progress that the Danish biotech has made in his two and a half years as CEO. Dulac also highlights…

Singapore Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs to be developed, and how Novartis has been working with patients in the region around its CAR-T therapies.   It…